Centogene Adds New Transcriptomic Offering to Multiomic Diagnostic Portfolio
Centogene announced the expansion of MOx, the company’s multiomic diagnostic portfolio, now incorporating transcriptomic analysis.
Read MorePosted by Andy Lundin | Oct 10, 2023 | Sequencing Systems |
Centogene announced the expansion of MOx, the company’s multiomic diagnostic portfolio, now incorporating transcriptomic analysis.
Read MorePosted by Andy Lundin | Oct 9, 2023 | Prostate |
Researchers developed a patent-pending method and algorithm to predict prostate cancer recurrence in patients treated by radiation therapy.
Read MorePosted by Andy Lundin | Oct 9, 2023 | Sequencing Systems, Unknown Origin & Other Cancer Types |
The new NGS test detects gene fusions, translocations, and rearrangements across 361 genes from FFPE tumor tissue.
Read MorePosted by Andy Lundin | Oct 4, 2023 | Cancer, Company News |
EValuate Diagnostics aims to make tests that detect cancer early, and will market a system for the capture of extracellular vesicles.
Read MorePosted by Andy Lundin | Oct 4, 2023 | Diagnostic Technologies |
IHDLab launched an API platform to help digital health companies enhance the efficiency and scalability of their at-home testing capabilities.
Read More